Knowing what we are good at, understanding what we can be best at, and consistently investing into development in these areas has been the key to PSI’s growth and established success on the market place.
Timely delivery of patient enrollment achieved consistently across multiple indications and studies of various sizes and levels of complexity is one of the key feastures clearly differentiating PSI from competition. 98% of PSI studies complete patient enrollment on or ahead of schedule. We attribute this success rate to (1) thorough feasibility assessments performed by dedicated feasibility staff worldwide; (2) go-the-extra-mile project management; (3) ability to harness the huge recruitment potential of the emerging markets, with a lot of effort invested into training, logistical support and closer monitoring.
Consistent delivery on enrollment promises and FDA/EMEA-approved quality of PSI data have contributed to PSI’s exceptionally high repeat and referral business rate.
PSI employs 1,000 staff worldwide, including 250 MDs. This allows us to provide expert support of clinical trials in a variety of indications.
Please contact us today to discuss feasibility of your clinical trial.